My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
NIIT tumbles after CEO resigns
Apr 10,2017

The announcement was made after market hours on Friday, 7 April 2017.

Meanwhile, the S&P BSE Sensex was down 74.94 points, or 0.25% to 29,631.67.

On the BSE, 22.85 lakh shares were traded in the counter so far, compared with average daily volumes of 2.01 lakh shares in the past one quarter. The stock had hit a high of Rs 80.40 and a low of Rs 73.80 so far during the day.

The stock hit a 52-week high of Rs 107.80 on 20 September 2016. The stock hit a 52-week low of Rs 67 on 9 November 2016.

The stock had outperformed the market over the past one month till 7 April 2017, rising 9.66% compared with 2.69% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 6.49% as against Sensexs 11.01% rise.

The small-cap company has equity capital of Rs 33.15 crore. Face value per share is Rs 2.

NIIT said that its chief executive officer (CEO), Rahul Keshav Patwardhan, tendered his resignation due to compelling family reasons and has requested to be relieved from the close of business hours of 31 July 2017. The Board has accepted his resignation at its meeting held on 7 April 2017.

Further, the board of directors has approved the appointment of Sapnesh Lalla as chief executive officer designate of the company from 7 April 2017 and as chief executive officer of the company with effect from 1 August 2017.

On a consolidated basis, net profit of NIIT declined 56.20% to Rs 6 crore on 1.91% rise in net sales to Rs 267.30 crore in Q3 December 2016 over Q3 December 2015.

NIIT, a global leader in skills and talent development, offers multi-disciplinary learning management and training delivery solutions to corporations, institutions, and individuals in over 40 countries. NIIT has three main lines of business across the globe- corporate learning group, skills and careers group, and school learning group.

Powered by Capital Market - Live News

Volumes jump at Shiva Cement counter
Apr 10,2017

Shiva Cement clocked volume of 45.83 lakh shares by 13:20 IST on BSE, a 70.81-times surge over two-week average daily volume of 65,000 shares. The stock rose 1.08% to Rs 23.50.

Sterling Tools notched up volume of 3.43 lakh shares, a 40.65-fold surge over two-week average daily volume of 8,000 shares. The stock rose 4.88% to Rs 232.

Moschip Semiconductor Technology saw volume of 32.09 lakh shares, a 12.98-fold surge over two-week average daily volume of 2.47 lakh shares. The stock rose 9.98% to Rs 52.90.

Linde India clocked volume of 1.08 lakh shares, a 12.52-fold surge over two-week average daily volume of 9,000 shares. The stock jumped 8.9% to Rs 473.90.

NIIT saw volume of 21.90 lakh shares, a 7.88-fold rise over two-week average daily volume of 2.78 lakh shares. The stock dropped 6.22% to Rs 77.70.

Powered by Capital Market - Live News

Cox & Kings gains on bottom fishing
Apr 10,2017

Meanwhile, the S&P BSE Sensex was down 104.37 points, or 0.35%, to 29,602.24. Meanwhile, the S&P BSE Mid-Cap index was up 33.76 points, or 0.24%, to 14,266.92

On the BSE, so far 11,000 shares were traded in the counter, compared with average daily volumes of 41,685 shares in the past one quarter. The stock had hit a high of Rs 216.35 and a low of Rs 212.20 so far during the day. The stock hit a 52-week high of Rs 242 on 19 September 2016. The stock hit a 52-week low of Rs 146.20 on 31 May 2016.

The mid-cap company has equity capital of Rs 88.28 crore. Face value per share is Rs 5.

The stock had outperformed the market over the past one month till 7 April 2017, surging 13.84% compared with 2.69% rise in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 13.81% as against Sensexs 11.01% rise.

Cox & Kings consolidated net profit slumped 84.81% to Rs 15.23 crore on 19.9% decline in net sales to Rs 1373.89 crore in Q3 December 2016 over Q3 December 2015.

Cox & Kings is a leading leisure and education travel group with operations in 22 countries across 4 continents. C&K operates in three key verticals: leisure, education and hybrid hotels.

Powered by Capital Market - Live News

RBL Bank zooms 21.12% in seven sessions
Apr 10,2017

Meanwhile, the S&P BSE Sensex was down 55.72 points, or 0.19% at 29,650.89.

On the BSE, 5.95 lakh shares were traded on the counter so far as against the average daily volumes of 3.19 lakh shares in the past one quarter. The stock had hit a high of Rs 598.70 so far during the day, which is also its record high. The stock had hit a low of Rs 561.05 so far during the day.

The stock had hit a 52-week low of Rs 273.70 on 31 August 2016. The stock had outperformed the market over the past one month till 7 April 2017, advancing 17.52% compared with the Sensexs 2.44% rise. The scrip had also outperformed the market over the past one quarter advancing 56.54% as against the Sensexs 11.01% rise.

The large-cap bank has equity capital of Rs 375.20 crore. Face value per share is Rs 10.

Shares of RBL Bank zoomed 21.12% in seven trading sessions to its current ruling price of Rs 588.40, from a close of Rs 485.80 on 29 March 2017.

RBL Banks net profit rose 58.8% to Rs 128.69 crore on 39% growth in net total income to Rs 1143.48 crore in Q3 December 2016 over Q3 December 2015.

RBL Bank is a private sector bank. It currently services over two million customers through a network of 215 branches and 374 ATMs spread across 16 Indian states and Union Territories. The bank offers specialized services under six business verticals namely: Corporate & Institutional Banking, Commercial Banking, Branch & Business Banking, Agribusiness Banking, Development Banking and Financial Inclusion, Treasury and Financial Markets Operations.

Powered by Capital Market - Live News

Sobha tops losers on BSEs A group
Apr 10,2017

Sobha slipped 8.47% at Rs 380.35. The stock topped the losers in A group. On the BSE, 80,000 shares were traded on the counter so far as against the average daily volumes of 6.24 lakh shares in the past two weeks.

Reliance Communications slipped 3.83% at Rs 37.70. The stock was the second biggest loser in A group. On the BSE, 14.66 lakh shares were traded on the counter so far as against the average daily volumes of 19.31 lakh shares in the past two weeks.

Indiabulls Housing Finance slipped 2.83% at Rs 928.40 . The stock was the third biggest loser in A group. On the BSE, 44,000 shares were traded on the counter so far as against the average daily volumes of 9.37 lakh shares in the past two weeks.

Oracle Financial Services Software slipped 2.52% at Rs 3,737.90. The stock was the fourth biggest loser in A group. On the BSE, 3,430 shares were traded on the counter so far as against the average daily volumes of 9.56 lakh shares in the past two weeks.

Prestige Estates Projects slipped 2.28% at Rs 216.30. The stock was the fifth biggest loser in A group. On the BSE, 6,886 shares were traded on the counter so far as against the average daily volumes of 52,000 shares in the past two weeks.

Powered by Capital Market - Live News

Indiabulls Ventures drops after recent rally
Apr 10,2017

The announcement was made after market hours on Friday, 7 April 2017.

Meanwhile, the S&P BSE Sensex was up 25.89 points, or 0.09% at 29,732.50. The S&P BSE Small-Cap index was up 121.28 points, or 0.83% at 14,802.70.

On the BSE, 13.64 lakh shares were traded on the counter so far as against the average daily volumes of 10.48 lakh shares in the past one quarter. The stock hit a high of Rs 74.15 in intraday trade so far, which is 52-week high for the counter. The stock hit a low of Rs 67.15 so far during the day. The stock had hit a 52-week low of Rs 14.55 on 9 May 2016.

The stock had outperformed the market over the past one month till 7 April 2017, surging 94.36% compared with 2.69% rise in the Sensex. The scrip had also outperformed the market in past one quarter, galloping 225.58% as against Sensexs 11.01% rise.

The small-cap company has equity capital of Rs 64.04 crore. Face value per share is Rs 2.

Indiabulls Ventures board of directors at its meeting held on 7 April 2017, approved preferential offer and issue of 3.88 crore equity shares at Rs 58.40 per share to Cinnamon Capital, a foreign portfolio investor. The total equity investment by Cinnamon Capital would aggregate to Rs 226.97 crore. The issue of shares is to augment long-term resources of the company for meeting funding requirements for business purposes, Indiabulls Ventures said.

Indiabulls Ventures consolidated net profit fell 54.1% to Rs 10.59 crore on 9.6% decline in total income from operation to Rs 96.93 crore in Q3 December 2016 over Q3 December 2015.

Indiabulls Ventures (Formerly known as Indiabulls Securities) is one of the leading company in the segment of Capital Market and Real Estate marketing and distribution.

Powered by Capital Market - Live News

Ajanta Pharma rises after USFDA clears Dahej facility
Apr 10,2017

The announcement was made during trading hours today, 10 April 2017.

Meanwhile, the S&P BSE Sensex was up 19.42 points, or 0.07% to 29,726.03.

On the BSE, 26,000 shares were traded in the counter so far, compared with average daily volumes of 25,063 shares in the past one quarter. The stock had hit a high of Rs 1,818 and a low of Rs 1,718.50 so far during the day. The stock hit a record high of Rs 2,150 on 28 October 2016. The stock hit a 52-week low of Rs 1,400.05 on 24 June 2016.

The stock had underperformed the market over the past one month till 7 April 2017, rising 0.45% compared with 2.69% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 4.14% as against Sensexs 11.01% rise.

The large-cap company has equity capital of Rs 17.60 crore. Face value per share is Rs 2.

Ajanta Pharma announced that its formulation facility at Dahej was inspected by US Food and Drug Administration (USFDA) from 3rd to 7th April 2017. At the end of the inspection, no Form 483 was issued to the company.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

On a consolidated basis, net profit of Ajanta Pharma rose 25.15% to Rs 142.60 crore on 9.68% rise in net sales to Rs 515.02 crore in Q3 December 2016 over Q3 December 2015.

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages.

Powered by Capital Market - Live News

Sobha tumbles on stake sale by promoter
Apr 10,2017

The announcement was made after market hours on Friday, 7 April 2017.

Meanwhile, the S&P BSE Sensex was up 48.24 points, or 0.16% at 29,754.85. The S&P BSE Mid-cap index was up 88.62 points, 0.62% at 14,321.78.

On the BSE, 68,000 shares were traded on the counter so far as against the average daily volumes of 1.17 lakh shares in the past one quarter. The stock had hit a high of Rs 403.95 and a low of Rs 378.50 so far during the day.

The stock had hit a 52-week high of Rs 423.30 on 7 April 2017 and a 52-week low of Rs 224.05 on 22 November 2016. The stock had outperformed the market over the past one month till 7 April 2017, advancing 27.47% compared with the Sensexs 2.44% rise. The scrip had also outperformed the market over the past one quarter advancing 56.25% as against the Sensexs 11.01% rise.

The mid-cap company has equity capital of Rs 96.30 crore. Face value per share is Rs 10.

Sobha said that the promoter Sobha Menon sold 40 lakh shares, or 4.15% stake at price of Rs 414.90 per share. Promoter Sobha Menon held 41.90% stake as per share holding as on 31 December 2016.

Adawi Investments Holdings bought 41.60 lakh shares at price of Rs 414.89 per share of the company.

Sobhas consolidated net profit rose 7.9% to Rs 39.40 crore on 24.4% increase in net sales to Rs 540 crore in Q3 December 2016 over Q3 December 2015.

Sobha Group is one of the largest real estate organisations in India and the Middle East. It has presence in 24 cities and 13 states across India and throughout the Middle East.

Powered by Capital Market - Live News

Divis Laboratories jumps as USFDA alters import alert list
Apr 10,2017

The announcement was made on Saturday, 8 April 2017.

Meanwhile, the S&P BSE Sensex was up 34.67 points, or 0.12% to 29,741.28.

On the BSE, 3.07 lakh shares were traded in the counter so far, compared with average daily volumes of 2.78 lakh shares in the past one quarter. The stock had hit a high of Rs 656.15 and a low of Rs 642.75 so far during the day. The stock hit a record high of Rs 1,380 on 16 September 2016. The stock hit a 52-week low of Rs 611.60 on 22 March 2017.

The stock had underperformed the market over the past one month till 7 April 2017, falling 18.09% compared with 2.69% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 15.59% as against Sensexs 11.01% rise.

The large-cap company has equity capital of Rs 53.09 crore. Face value per share is Rs 2.

Divis Laboratories said the United States Food and Drug Administration (USFDA) has exempted some more products manufactured at the companys Unit-II at Visakhapatnam from the import alert issued under clauses 66-40 & 99-32 of the FDA regulations.

An import alert prohibits the company to manufacture or market that particular drug in the United States, according to the regulators website.

Last month, Divis Laboratories announced that the USFDA issued an Import Alert 66-40 on 20 March 2017 on the products manufactured at the companys Unit-II at Visakhapatnam, Andhra Pradesh. The agency has exempted the 10 products namely Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen Sodium, Raltegravir potassium, Atovaquone, Chloropurine , BOC core succinate and 2, 4-wing active ester, from the import alert, it added.

Divis Laboratories net profit rose 8.7% to Rs 268.32 crore on 13.4% increase in net sales to Rs 973.44 crore in Q3 December 2016 over Q3 December 2015.

Divis Laboratories is primarily engaged in the manufacture of active pharmaceutical ingredients (APIs) & intermediates for generics; custom synthesis of APIs and advanced intermediates for discovery compounds for pharma giants; building blocks for peptides; building blocks for nucleotides; carotenoids; and chiral ligands.

Powered by Capital Market - Live News

Apollo Tyres inflates after inaugurating Hungarian plant
Apr 10,2017

The announcement was made after market hours on Friday, 7 April 2017.

Meanwhile, the BSE Sensex was up 5.15 points, or 0.02%, to 29,711.76.

On BSE, so far 1.53 lakh shares were traded in the counter, compared with average daily volume of 3.36 lakh shares in the past two weeks. The stock hit a high of Rs 217.50 and a low of Rs 214.50 so far during the day. The stock hit a 52-week high of Rs 235 on 6 October 2016. The stock hit a 52-week low of Rs 139.35 on 24 June 2016.

The stock had outperformed the market over the past one month till 7 April 2017, rising 18.23% compared with 2.69% rise in the Sensex. The scrip had also outperformed the market in past one quarter, surging 12.75% as against Sensexs 11.01% rise.

The large-cap company has equity capital of Rs 50.90 crore. Face value per share is Re 1.

Apollo Tyres announced inauguration of the companys sixth global tyre manufacturing unit and the second one in Europe. Located less than 100 km from the capital Budapest, it is the companys first greenfield facility outside India. Built over 72 hectares, construction began on site in April 2015.

Apollo Tyres is investing Euro 475 million in this facility. The final capacity at the end of phase I would be 5.5 million passenger car & light truck (PCLT) tyres and 675,000 commercial vehicle tyres. This facility will complement Apollo Tyres existing facility in the Netherlands, and will produce both Apollo and Vredestein brand of tyres for the European market.

Speaking on the occasion Onkar S Kanwar, Chairman, Apollo Tyres said that the Hungarian facility will help the company further increase its presence and market share in Europe. From being a replacement market focussed company in Europe, the company would soon be starting supplies of tyres to all the leading OEs in Europe.

Apollo Tyres consolidated net profit rose 5.98% to Rs 295.70 crore on 17.76% increase in total income to Rs 3495.21 crore in Q3 December 2016 over Q3 December 2015.

Apollo Tyres is an international tyre major with manufacturing units in India, the Netherlands and Hungary. The company markets its products under its two global brands - Apollo and Vredestein. The companys products are available in over 100 countries through a network of branded, exclusive and multi-product outlets.

Powered by Capital Market - Live News

Bhushan Steel spurts on report of loan restructuring
Apr 10,2017

Meanwhile, the S&P BSE Sensex was up 21.89 points, or 0.07% to 29,728.50.

On the BSE, 1.86 lakh shares were traded in the counter so far, compared with average daily volumes of 2.08 lakh shares in the past one quarter. The stock had hit a high of Rs 65.20 and a low of Rs 63 so far during the day.

The stock hit a 52-week high of Rs 65.20 on 10 April 2017. The stock hit a 52-week low of Rs 34.50 on 24 May 2016.

The stock had outperformed the market over the past one month till 7 April 2017, rising 10.94% compared with 2.69% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 43.35% as against Sensexs 11.01% rise.

The small-cap company has equity capital of Rs 45.30 crore. Face value per share is Rs 2.

According to the media report, Bhushan Steel last month submitted final proposal for debt restructuring under the Reserve Bank of India (RBI)s S4A scheme. S4A, or Scheme for Sustainable Structuring of Stressed Assets, was unveiled by RBI last year to make debt recasts easier.

Bhushan Steel has been in financial distress recently. State Bank of India and Punjab National Bank lead two groups of creditor banks to Bhushan Steel. As of 2015-2016, the steel maker had Rs 44477.90 crore debt on books with Rs 10000 crore being added in past three years as interest and penal interest, reports added.

Under S4A scheme, banks need to establish by a process that involves a forensic audit that the promoters are clean and not involved in any activity of malfeasance. S4A cannot be implemented if the audit report suggests problem with the promoters. In such cases where wrong doing is seen on the part of promoters, the S4A can be implemented only when there is a change in ownership.

Bhushan Steel reported net loss of Rs 734.04 crore in Q3 December 2016 as against net loss of Rs 693.60 crore in Q3 December 2015. Net sales rose 47.12% to Rs 3611.13 crore in Q3 December 2016 over Q3 December 2015.

Bhushan Steel is one of the prominent players in the Indian steel industry. It has an existing steel production capacity of 5.6 million ton per annum.

Powered by Capital Market - Live News

Brigade Enterprises rises after launch of luxury project
Apr 10,2017

The announcement was made after market hours on Friday, 7 April 2017.

Meanwhile, the S&P BSE Sensex was down 2.59 points, or 0.01%, to 29,704.02. Meanwhile, the S&P BSE Small-Cap index was up 50.39 points, or 0.34%, to 14,731.81

On BSE, so far 697 shares were traded in the counter, compared with average daily volume of 37,594 shares in the past one quarter. The stock hit a high of Rs 244.90 and a low of Rs 242.25 so far during the day. The stock hit a 52-week high of Rs 251.90 on 5 April 2017. The stock hit a 52-week low of Rs 138.30 on 8 April 2016.

The stock had outperformed the market over the past one month till 7 April 2017, rising 21.14% compared with 2.69% rise in the Sensex. The scrip had also outperformed the market in past one quarter, surging 57.73% as against Sensexs 11.01% rise.

The small-cap company has an equity capital of Rs 113.66 crore. Face value per share is Rs 10.

Brigade Buena Vista consists of 4 elegant residential towers spread across 7 acres, large parts of which are reserved for green, open spaces. The project is strategically located with excellent 3-way connectivity to Whitefield, Central and North Bengaluru and offers a strategic mix of accessibility and convenient living.

Brigade Enterprises consolidated net profit declined 12.41% to Rs 30.41 crore on 14.46% fall in net sales to Rs 537.61 crore in Q3 December 2016 over Q3 December 2015.

Brigade Enterprises is Brigade groups flagship company. Brigade group was established in 1986, with property development as its main focus.

Powered by Capital Market - Live News

Dilip Buildcon firms up after winning two EPC projects in Maharashtra
Apr 10,2017

The announcement was made before trading hours today, 10 April 2017.

Meanwhile, the S&P BSE Sensex was down 27.93 points, or 0.09% to 29,678.68.

On the BSE, 5,132 shares were traded in the counter so far, compared with average daily volumes of 39,896 shares in the past one quarter. The stock had hit a high of Rs 362.35 and a low of Rs 358 so far during the day.

The stock hit a record high of Rs 373.80 on 5 April 2017. The stock hit a record low of Rs 178.60 on 9 November 2016.

The stock had outperformed the market over the past one month till 7 April 2017, rising 11.63% compared with 2.69% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 55.31% as against Sensexs 11.01% rise.

The mid-cap company has equity capital of Rs 136.77 crore. Face value per share is Rs 10.

Dilip Buildcon has received Letter of Award (LoA) from the Ministry of Road Transport & Highways (MORTH), Government of India for two EPC (engineering, procurement and construction) road projects worth Rs 580.50 crore in Maharashtra.

The first project is for rehabilitation and up-gradation of two lane with paved shoulders on; EPC mode from Kalamb to Wadki (Kalamb - Ralegaon - Wadki). The second project is for rehabilitation and up-gradation of two lane with paved shoulder on EPC mode, from Majalgaon to Kaij.

Dilip Buildcons net profit jumped 151.7% to Rs 108.64 crore on 41.9% rise in net sales to Rs 1388.43 crore in Q3 December 2016 over Q3 December 2015.

Dilip Buildcon is a road-focused engineering procurement construction (EPC) contractor. The company develops infrastructure across the country in diverse areas such as roads & bridges, water sanitation & sewage, irrigation, industrial, commercial & residential buildings.

Powered by Capital Market - Live News

SMS Pharma in pink of health after hiking stake in VKT Pharma
Apr 07,2017

The announcement was made after market hours yesterday, 6 April 2017.

Meanwhile, the BSE Sensex was down 216.62 points, or 0.72%, to 29,710.72. Meanwhile, the BSE Small-Cap index was down 65.58 points, or 0.44%, to 14,685.39.

On BSE, so far 84,000 shares were traded in the counter, compared with an average volume of 11,669 shares in the past one quarter. The stock hit a high of Rs 93.90 and a low of Rs 88 so far during the day. The stock hit a 52-week high of Rs 115 on 6 October 2016. The stock hit a 52-week low of Rs 78 on 21 November 2016.

The stock had underperformed the market over the past one month till 6 April 2017, rising 0.86% compared with the Sensexs 3.55% rise. The scrip also underperformed the market over the past one quarter, sliding 7.3% as against the Sensexs 11.84% advance.

The small-cap company has an equity capital of Rs 8.47 crore. Face value per share is Re 1.

SMS Pharmaceuticals said that the company has further invested Rs 2.7 crore by subscribing 1.20 lakh equity shares at Rs 225 per share. After the present acquisition, the total holding of the company in VKT Pharma stood at 41.08%, SMS Pharmaceuticals said.

Net profit of SMS Pharmaceuticals rose 18.33% to Rs 13.04 crore on 16.82% rise in net sales to Rs 167.98 crore in Q3 December 2016 over Q3 December 2015.

SMS Pharmaceuticals is a global player in active pharmaceutical ingredient (API) manufacturing.

Powered by Capital Market - Live News

Cadila Healthcare moves up after facility clears USFDA inspection
Apr 07,2017

The announcement was made during market hours today, 7 April 2017.

Meanwhile, the S&P BSE Sensex was down 199.81 points or 0.67% at 29,727.53.

Higher than normal volumes were witnessed on the counter. On the BSE, 9.26 lakh shares were traded on the counter so far as against the average daily volumes of 1.3 lakh shares in the past one quarter. The stock had hit a high of Rs 466.10 in intraday trade, which is also a record high for the stock. The stock hit a low of Rs 447.50 so far during the day. The stock had hit a 52-week low of Rs 305 on 12 April 2016.

The stock had underperformed the market over the past one month till 6 April 2017, gaining 2.18% compared with Sensexs 3.03% gains. The scrip had, however, outperformed the market in past one quarter, advancing 18.14% as against Sensexs 11.84% rise.

The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.

Cadila Healthcare announced that United States Food & Drug Administration (USFDA) issued no observation (483) after inspecting companys Topical manufacturing facility in Changodar near Ahmedabad from 3 April to 7 April 2017.

The company has filed 17 products with the USFDA from this manufacturing facility, it added.

Cadila Healthcares consolidated net profit fell 34.6% to Rs 281.60 crore on 0.8% decline in net sales to Rs 2249.60 crore in Q3 December 2016 over Q3 December 2015.

Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Powered by Capital Market - Live News